[go: up one dir, main page]

EE200300260A - Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid - Google Patents

Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid

Info

Publication number
EE200300260A
EE200300260A EEP200300260A EEP200300260A EE200300260A EE 200300260 A EE200300260 A EE 200300260A EE P200300260 A EEP200300260 A EE P200300260A EE P200300260 A EEP200300260 A EE P200300260A EE 200300260 A EE200300260 A EE 200300260A
Authority
EE
Estonia
Prior art keywords
receptor antagonists
adenosine receptor
purine derivatives
condensed purine
condensed
Prior art date
Application number
EEP200300260A
Other languages
English (en)
Inventor
Lin Ko-Chung
Vu Chi
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200300260A publication Critical patent/EE200300260A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300260A 2000-12-01 2001-11-30 Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid EE200300260A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01
PCT/US2001/044991 WO2002044182A1 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
EE200300260A true EE200300260A (et) 2003-08-15

Family

ID=22948640

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300260A EE200300260A (et) 2000-12-01 2001-11-30 Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid

Country Status (32)

Country Link
US (2) US6605601B2 (et)
EP (1) EP1347981B1 (et)
JP (2) JP2004514723A (et)
KR (1) KR20040011439A (et)
CN (1) CN100497340C (et)
AR (1) AR035400A1 (et)
AT (1) ATE394402T1 (et)
AU (2) AU2002219977B2 (et)
BG (1) BG107849A (et)
BR (1) BR0115833A (et)
CA (1) CA2430508C (et)
CZ (1) CZ20031513A3 (et)
DE (1) DE60133931D1 (et)
EA (1) EA009814B1 (et)
EE (1) EE200300260A (et)
ES (1) ES2305139T3 (et)
GE (1) GEP20094697B (et)
HU (1) HUP0400530A3 (et)
IL (1) IL156046A0 (et)
IS (1) IS6821A (et)
MX (1) MXPA03004857A (et)
MY (1) MY127120A (et)
NO (1) NO20032483L (et)
NZ (1) NZ526511A (et)
PL (1) PL362642A1 (et)
SK (1) SK6552003A3 (et)
TR (1) TR200300766T2 (et)
TW (1) TWI293301B (et)
UA (1) UA75625C2 (et)
WO (1) WO2002044182A1 (et)
YU (1) YU42903A (et)
ZA (2) ZA200304067B (et)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2238335T3 (es) * 1999-12-24 2005-09-01 Kyowa Hakko Kogyo Co., Ltd. Derivados de purina condensados.
CZ20031513A3 (cs) * 2000-12-01 2003-09-17 Biogen, Inc. Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru
WO2004074247A2 (en) * 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
RU2367442C2 (ru) * 2003-04-25 2009-09-20 Новокардия, Инк. Способ нормализации мочеиспускания при нарушении функции почек
US20060252780A1 (en) * 2003-04-25 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. Fused pyrimidine derivatives
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
CA2601032A1 (en) * 2005-03-11 2006-09-21 Aderis Pharmaceuticals, Inc. Substituted 9-alkyladenines and the use thereof
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
AU2007235372A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine A1 receptor antagonists and anticonvulsants
MX2008014672A (es) 2006-05-19 2009-03-09 Abbott Lab Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central.
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
WO2007150026A2 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
JP5584466B2 (ja) 2006-06-23 2014-09-03 インサイト コーポレイション ＨＭ７４ａ受容体アゴニストとしてのプリノン誘導体
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
SG11202006435XA (en) 2018-01-04 2020-08-28 Impetis Biosciences Ltd Tricyclic compounds, compositions and medicinal applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
ES2152207T3 (es) * 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk Derivados condensados de la purina.
ATE178060T1 (de) 1991-09-23 1999-04-15 Univ Florida State Darstellung von substituierten isoserinestern unter verwendung von metallalkoxiden und s- lactamen
EP0884318A4 (en) * 1996-10-07 2002-10-23 Kyowa Hakko Kogyo Kk CONDENSED PURINE DERIVATIVES
JP2002505687A (ja) * 1997-06-18 2002-02-19 ディスカバリー セラピューティクス，インコーポレイテッド 脈管再生手順の後の再狭窄を防止するための組成物および方法
US6489331B1 (en) * 1998-07-02 2002-12-03 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
ES2238335T3 (es) * 1999-12-24 2005-09-01 Kyowa Hakko Kogyo Co., Ltd. Derivados de purina condensados.
CZ20031513A3 (cs) * 2000-12-01 2003-09-17 Biogen, Inc. Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru

Also Published As

Publication number Publication date
KR20040011439A (ko) 2004-02-05
MY127120A (en) 2006-11-30
ZA200304067B (en) 2005-05-30
UA75625C2 (en) 2006-05-15
EA009814B1 (ru) 2008-04-28
NO20032483L (no) 2003-07-30
BR0115833A (pt) 2003-10-28
BG107849A (bg) 2004-01-30
US20030220358A1 (en) 2003-11-27
ATE394402T1 (de) 2008-05-15
AR035400A1 (es) 2004-05-26
CA2430508A1 (en) 2002-06-06
EP1347981B1 (en) 2008-05-07
ES2305139T3 (es) 2008-11-01
JP2010053148A (ja) 2010-03-11
US6605601B2 (en) 2003-08-12
US7022686B2 (en) 2006-04-04
AU1997702A (en) 2002-06-11
TR200300766T2 (tr) 2004-09-21
IS6821A (is) 2003-05-20
HUP0400530A2 (hu) 2004-06-28
HUP0400530A3 (en) 2007-05-29
GEP20094697B (en) 2009-06-10
CN1481387A (zh) 2004-03-10
CZ20031513A3 (cs) 2003-09-17
HK1059927A1 (en) 2004-07-23
PL362642A1 (en) 2004-11-02
MXPA03004857A (es) 2003-08-19
NZ526511A (en) 2005-04-29
EA200300629A1 (ru) 2003-12-25
AU2002219977B2 (en) 2008-01-24
JP2004514723A (ja) 2004-05-20
DE60133931D1 (de) 2008-06-19
IL156046A0 (en) 2003-12-23
CA2430508C (en) 2010-05-18
TWI293301B (en) 2008-02-11
YU42903A (sh) 2006-05-25
EP1347981A1 (en) 2003-10-01
SK6552003A3 (en) 2003-12-02
NO20032483D0 (no) 2003-06-02
ZA200408755B (en) 2005-07-27
CN100497340C (zh) 2009-06-10
US20020111333A1 (en) 2002-08-15
WO2002044182A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
EE200300260A (et) Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid
DK1283839T3 (da) Adenosin A2a-receptorantagonister
ATE317844T1 (de) Adenosine a2a receptor antagonisten
ATE453647T1 (de) Adenosin a2a rezeptor antagonisten
IL178396A0 (en) Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
HUP0401925A3 (en) A2b adenosine receptor antagonists
IL154079A0 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
PT1296996E (pt) Derivados de purina
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
HUP0401437A3 (en) Adenosine a3 receptor agonists
ATE358130T1 (de) Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten
DE59712958D1 (de) Substituierte Purinderivate als Vitronectinrezeptor-Antagonisten
IL153837A0 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
DK1208100T3 (da) Selektive antagonister af A2B adenosinreceptorer
NO20015662L (no) Oralt aktive A1-adenosinreseptorantagonister
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
ATE281456T1 (de) Aminotriazolopyridinderivate als adenosinrezeptorliganden
SI1401837T1 (sl) Purinski derivati kot antagonisti adenozinskega receptorja A2B
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
AU2002320199A1 (en) Purine derivatives as a2b adenosine receptor antagonists
HK1056359A (en) Purine derivatives as purinergic receptor antagonists
PL378983A1 (pl) Pochodne ksantyny jako antagoniści receptora adenozyny A2B

Legal Events

Date Code Title Description
HC1A Change of owner name